CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 468 enrolled
Drug / intervention
Talcid® +3 moredrug
Likely dose
Chinese medicine prescription 9gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02955134
NCT02955134N/ACompleted
CompareCT.gov

Follow-up Study of Chinese Medicine for the Treatment of Chronic Atrophic Gastritis Based on Histological Evaluation

Wangjing Hospital, China Academy of Chinese Medical Sciences·interventional·Posted Nov 4, 2016·Updated Mar 11, 2022

In Brief

A clinical study evaluating Talcid®, Chinese medicine prescription, and 2 other interventions for Chronic Atrophic Gastritis. Completed, enrolled 468 participants across 13 sites.

Detailed Summary

The purpose of this study is to evaluate efficacy of Chinese medicine treatment for chronic atrophic gastritis. It is a multi-center, randomized, placebo-controlled trial.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Atrophic Gastritis
CountriesChina
CollaboratorsBeijing University of Chinese Medicine, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Shaanxi Hospital of Traditional Chinese Medicine, Gansu Provincial Hospital, Tianjin Nankai Hospital, The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine, Guangdong Provincial Hospital of Traditional Chinese Medicine, Hebei Hospital of Traditional Chinese Medicine, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Shanxi Province hospital Research Institute of Traditional Chinese Medicine, Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, China-Japan Friendship Hospital

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedNov 4, 2016
Enrollment StartMar 12, 2018
Primary CompletionMay 1, 2021
Study CompletionNov 30, 2021
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 9.7 years ago

Interventions

Talcid®drug

Talcid® is allowed to be taken when patients feel stomach pain, acid reflux or heartburn. Continuous taking time should not exceed one week.

Chinese medicine prescriptiondrug

The Chinese medicine application prescription is composed of pinellia 9g, radix scutellariae 10g, rhizoma coptidis 8g, rhizoma zingiberis 10g, radix curcumae 10g, rhizoma atractylodis 10g, roasted bighead atractylodes rhizome 10g, radix astragali 15g, spreading hedyotis herb 20g, scutellariae barbatae 20g, salvia miltiorrhiza bge 10g, the stem of noble dendrobium 10g, radix pseudostellariae 10g, fructus aurantii immaturus 10g, cortex magnoliae officinalis 10g, rhizoma curcumae 10g, ginger 3g, jujube 6g. Patients take 200ml each time, twice a day. Treatment duration are 24 weeks.

Placebodrug

The placebo is simulate granule of Chinese medicine application prescription. Patients take 200ml each time, twice a day. Treatment duration are 24 weeks.

Compound Azimtamide Entieric-coated Tabletsdrug

Compound Azimtamide Entieric-coated Tablets are qualified by China Food and Drug Administration. These tablets are allowed to be taken when patients feel fullness, belching or anorexia. Continuous taking time should not exceed one week.